Wai-kwan A. Yung

Neurology
210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.

Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025

Oncogenic drivers shape the tumor microenvironment in human gliomas.

Oncogenic drivers shape the tumor microenvironment in human gliomas.

Journal: bioRxiv : the preprint server for biology
Published: June 06, 2025

Retraction Note: Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN.

Retraction Note: Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN.

Journal: Oncogene
Published: April 08, 2025

Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation.

Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation.

Journal: Nature genetics
Published: March 08, 2025

Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics.

Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics.

Journal: Nature genetics
Published: April 05, 2024

The multilayered transcriptional architecture of glioblastoma ecosystems.

The multilayered transcriptional architecture of glioblastoma ecosystems.

Journal: Nature genetics
Published: April 05, 2024

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.

Journal: Nature communications
Published: February 14, 2024

Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma.

Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma.

Journal: Neuro-oncology advances
Published: December 22, 2023

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 07, 2023

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.

Journal: Nature genetics
Published: October 28, 2021

Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.

Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.

Journal: Neuro-oncology advances
Published: October 25, 2021

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.

Journal: Neuro-oncology
Published: April 06, 2021
Showing 1-12 of 80

Last Updated: 09/26/2026